Valuation: KAIS PHARPAR

Market Cap 6.16M 5.29M 4.96M 4.53M 8.56M 588M 8.6M 58.74M 22.76M 296M 23.13M 22.63M 982M P/E 2026 *
-0.79x
P/E 2027 * -0.51x
Enterprise Value 6.16M 5.29M 4.96M 4.53M 8.56M 588M 8.6M 58.74M 22.76M 296M 23.13M 22.63M 982M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
66.39%
Yield 2026 *
-
Yield 2027 * -
1 day+4.75%
1 week-16.02%
Current month-15.06%
1 month-8.77%
3 months-49.73%
6 months-52.92%
Current year-63.38%
1 week 0.22
Extreme 0.22
0.3
1 month 0.22
Extreme 0.22
0.41
Current year 0.22
Extreme 0.22
1.04
1 year 0.22
Extreme 0.22
2.11
3 years 0.22
Extreme 0.22
4
5 years 0.22
Extreme 0.22
4
10 years 0.22
Extreme 0.22
4
Manager TitleAgeSince
Chief Executive Officer 61 2013-06-16
Director of Finance/CFO 66 2018-12-31
Chief Tech/Sci/R&D Officer 66 -
Director TitleAgeSince
Chairman 61 2013-06-16
Director/Board Member 56 2020-09-08
Director/Board Member 51 2024-09-10
Date Insider Type Main position Quantity % Market Cap.
10/8/25 Free

Chief Financial Officer

152,672 0.7360%
10/8/25 Free

Chief Executive Officer

190,840 0.9200%
10/8/25 Free

Director

19,084 0.0920%
Change 5-day change 1-year change 3-year change Capi.($)
+4.75%-16.02%-78.33% - 5.88M
+3.31%-3.70%+61.03%+103.64% 71.35B
+2.09%+2.28%+49.95%+91.30% 64.17B
-1.31%-0.50%+7.41%-4.29% 28.65B
+0.40%-4.80%-5.89%+469.55% 27.06B
-2.78%+5.95%+55.58%+14.43% 27.33B
-1.68%+0.33%+36.86%-16.09% 20.47B
+1.02%+6.43%+269.42%+420.34% 19.36B
-0.57%-0.57%+7.19%+515.61% 15.96B
-1.09%+3.14%+46.32%+155.12% 14.05B
Average +0.41%+1.65%+44.96%+194.40% 28.84B
Weighted average by Cap. +0.79%+3.29%+55.02%+154.12%

Financials

2026 *2027 *
Net sales - -
Net income -7.94M -6.82M -6.4M -5.84M -11.03M -757M -11.08M -75.72M -29.34M -382M -29.82M -29.17M -1.27B -14.16M -12.15M -11.41M -10.42M -19.66M -1.35B -19.76M -135M -52.32M -681M -53.17M -52.02M -2.26B
Net Debt - -
Logo KAIS PHARPAR
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. Its therapy includes antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its portfolio consists of seven drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301 and 401 and therapeutic agents ENV 105 and 205. KROS 101 is a small molecule that targets the glucocorticoid-induced tumor necrosis factor ligand-related (GITR) ligand, a signal for T cell growth to remove a checkpoint barrier to fight a host of cancers. KROS 201 is a T cell therapy activated by dendritic cells to treat glioblastoma, a deadly and common brain cancer. ENV 105 drug seeks to address unmet medical needs in large markets of prostate and lung cancers.
Employees
-
Date Price Change Volume
26-08-26 US$0.2600 +4.75% 674,510
26-08-25 US$0.2482 +6.98% 357,439
26-08-24 US$0.2320 -20.00% 1,724,838
26-08-21 US$0.2900 -1.73% 297,565
26-08-20 US$0.2951 -4.68% 248,566
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.2600USD
Average target price
7.000USD
Spread / Average Target
+2,592.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KAPA Stock